Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/25957
Title: | Hypotensive effects of intravenously administered uridine and cytidine in conscious rats: Involvement of adenosine receptors |
Authors: | Süzer, Öner Yaçın, Murat Uludağ Üniversitesi/Tıp Fakültesi/Farmakoloji ve Klinik Farmakoloji Anabilim Dalı. 0000-0001-9496-1475 Yılmaz, Mustafa Sertaç Coskun, Cenk Nuri Mutlu, Duygu Savci, Vahide AAH-1571-2021 8895544100 23667159700 23668710500 6603687024 |
Keywords: | A1 receptor A2A receptor Adenosine Cardiovascular Cytidine Purinergic Uridine Injected cdp-choline Blood-pressure Nitric-oxide A(1) Pharmacology Mechanisms Pharmacology & pharmacy |
Issue Date: | 14-Apr-2008 |
Publisher: | Elsevier |
Citation: | Yılmaz, M.S. vd. (2008). ''Hypotensive effects of intravenously administered uridine and cytidine in conscious rats: Involvement of adenosine receptors". European Journal of Pharmacology, 584(1), 125-136. |
Abstract: | In the present study, we investigated the cardiovascular effects of intravenously injected uridine or cytidine, and the role of adenosine receptors in mediating these effects, in conscious normotensive rats. Intravenous (i.v.) administration of uridine (124, 250, 500 mg/kg) dose-dependently decreased arterial pressure and heart rate. Cytidine (124, 250, 500 mg/kg; i.v.) produced slight dose-related hypotension without changing heart rate. Plasma uridine and cytidine concentrations increased time- and dose-dependently while plasma adenosine levels did not change after injection of the respective nucleosides. Pretreatment with intravenous caffeine (20 mg/kg), 8-phenyltheophylline (8-PT) (I mg/kg), nonselective adenosine receptor antagonists, or 8-p-sulfophenyltheophyl line (8-SPT) (20 mg/kg), a nonselective adenosine receptor antagonist which does not cross the blood-brain barrier, abolished the cardiovascular effects of uridine (250 mg/kg; i.v.) or cytidine (250 mg/kg; i.v.). Intracerebroventricular (i.c.v.) caffeine (200 mu g) or 8-SPT (50 lug) pretreatment did not change the magnitude of the cardiovascular responses induced by nucleosides. Intravenous 8-cyclopenthyl-1,3-dipropylxanthine (DPCPX) (5 mg/kg), a selective adenosine A, receptor antagonist, greatly attenuated the cardiovascular responses to uridine and cytidine. Pretreatment with 3,7,-dimethyl-1-propargylxanthine (DMPX) (2 mg/kg), an adenosine A(1)/A(2) receptor antagonist, attenuated hypotension induced by uridine and blocked the arterial pressure decrease in response to cytidine. Uridine-induced bradycardia was blocked by DMPX. 4-(2-[7-amino-2-(2-furyl[1,2,4]-triazolo[2,3-a[1,3,5]triazin-5-yl-aminoethyl)phenol (ZM241385) (1 mg/kg; i.v.), a selective adenosine A(2A) receptor antagonist, pretreatment produced an only very small blockade in the first minute of the hypotensive effects of uridine without affecting the bradycardia. ZM241385 pretreatment completely blocked cytidine's hypotensive effect. In Langendorff-perfused rat heart preparation, uridine (10(-3) M), but not cytidine, decreased the heart rate. Our results show that intravenously injected uridnme or cytidine is able to decrease arterial pressure by activating peripheral adenosine receptors. The data also implicates that the mainly adenosine A(1) receptor activation is involved in the uridine-induced cardiovascular effects, while both adenosine A(1) and A(2A) receptor activations mediate the cytidine's effects. |
URI: | https://doi.org/10.1016/j.ejphar.2008.01.044 https://www.sciencedirect.com/science/article/pii/S0014299908001301 http://hdl.handle.net/11452/25957 |
ISSN: | 0014-2999 1879-0712 |
Appears in Collections: | PubMed Scopus Web of Science |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.